CAR‐T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation

Abstract While there is intense interest in the production of allogeneic CAR‐T cells from umbilical cord units, little is known about the reactivity and persistence of CAR‐T cells of umbilical origin. We report the case of a patient at our hematological center with multiple relapsing Ph+ B‐ALL, notably a Blinatunomab non‐responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post‐allogeneic hematopoietic stem cell transplantation. The patient achieved a rapid CAR‐T expansion and durable remission presenting in good clinical conditions 6 months post‐CAR‐T infusion, without manifestations of graft‐versus‐host disease. The case report provides insight into the reactivity and persistence of CAR‐T cells of umbilical origin, confirming the potential promise of allogeneic umbilical cord‐derived CAR‐T cells.